*Evaluation of Patients for Radiotherapy for Prostate Adenocarcinoma DOI: http://dx.doi.org/10.5772/intechopen.109447*

[27] Draulans C, van der Heide UA, Haustermans K, et al. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiotherapy and Oncology. 2020;**147**:92-98

[28] Sheets NC, Goldin GH, Meyer AM, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. Journal of the American Medical Association. 2012;**307**(15): 1611-1620

[29] Morris WJ, Tyldesley S, Rodda S, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): An analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. IJROBP. 2017;**98**(2):275-285

[30] Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. The Lancet Oncology. 2011;**12**(5): 451-459

[31] Jones CU, Pugh SL, Sandler HM, et al. Adding short-term androgen deprivation therapy to radiation therapy in men with localized prostate cancer: Long-term update of the NRG/RTOG 9408 randomized clinical trial. IJROBP. 2022;**112**(2):294-303

[32] Murthy V, Maitre P, Kannan S, et al. Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): Outcomes from phase III randomized controlled trial. Journal of Clinical Oncology. 2021;**39**(11):1234-1242

[33] Hall WA, Paulson E, Davis BJ, et al. NRG oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer. IJROBP. 2021;**109**(1): 174-185

[34] Kishan AU, Sun Y, Hartman H, et al. Androgen deprivation therapy use and duration with definitive radiotherapy for localized prostate cancer: An individual patient data meta-analysis. The Lancet Oncology. 2022;**23**(2):304-316

[35] Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. NEJM. 2009;**360**:2516-2527

[36] Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet. 2002;**360**(9327):103-106

[37] Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. Journal of the National Cancer Institute. 2006; **98**(10):715-717

[38] Ko EC, Michaud AL, Valicenti RK. Postoperative radiation after radical prostatectomy. Seminars Radiation Oncology. 2017;**27**(1):50-66

[39] Vale CL, Fisher D, Kneebone A, et al. Adjuvant or early salvage radiotherapy for the treatment of localized and locally advanced prostate cancer: A prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020;**396**(10260):1422-1431

[40] Valicenti RK, Thompson I Jr, Albertsen P, et al. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American urological association guidelines. IJROBP. 2013; **86**(5):822-828

[41] Kruser TJ, Jarrard DJ, Graf AK, et al. Early hypofractionated salvage radiotherapy for prostatectomy biochemical recurrence. Cancer. 2011; **117**(12):2629-2636

[42] Katayama S, Striecker T, Kessel K, et al. Hypofractionated IMRT of the prostate bed after radical prostatectomy: Acute toxicity in the PRIAMOS-1 trial. IJROBP. 2014;**90**(4):926-933

[43] Gladwish A, Loblaw A, Cheung P, et al. Accelerated hypofractionated postoperative radiotherapy for prostate cancer: A prospective phase I/II study. Clinical Oncology (Royal College of Radiologists). 2015;**27**(3):145-152

[44] NRG-GU003: A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT). NRG Oncology. Available from: https://www.nrgoncology. org/Clinical-Trials/Protocol/nrg-gu003?f ilter=nrg-gu003 [Accessed: November 26, 2022]

[45] Shipley WU, Seiferheld W, Lukka H, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. NEJM. 2017;**376**(5): 417-428

[46] Carrie C, Magné N, Burban-Provost P, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): A 112-month followup of a phase 3, randomized trial. The Lancet Oncology. 2019;**20**(12):1740-1749

[47] Pollack A, Karrison TG, Balogh AG, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG oncology/RTOG 0534 SPPORT): An international, multicentre, randomized phase 3 trial. Lancet. 2022;**399**(10338):1886-1901

[48] Sheth N, Youssef I, Osborn V, et al. Association of Nadir Prostate-specific Antigen >0.5 ng/mL after dose-escalated external beam radiation with prostate cancer-specific endpoints. Cureus. 2018; **10**(6):e2790

[49] Crook J, Rodgers JP, Pisansky TM, et al. Salvage low-dose-rate prostate brachytherapy: Clinical outcomes of a phase 2 trial for local recurrence after external beam radiation therapy (NRG oncology/RTOG 0526). IJROBP. 2022; **112**(5):1115-1122

[50] Valle LF, Lehrer EJ, Markovic D, et al. A systematic review and metaanalysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). European Urology. 2021; **80**(3):280-292

[51] Boevé LMS, Hulshof MCCM, Vis AN, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: Data from the HORRAD trial. European Urology. 2019; **75**(3):410-418

[52] Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomized controlled phase 3 trial. Lancet. 2018;**392**(10162): 2353-2366

*Evaluation of Patients for Radiotherapy for Prostate Adenocarcinoma DOI: http://dx.doi.org/10.5772/intechopen.109447*

[53] Parker CC, James ND, Brawley CD, et al. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomized controlled trial. PLOS Medicine. 2022;**19**(6):e1003998

[54] Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for Oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial. JAMA Oncology. 2020;**6**(5):650-659

[55] Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for Oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial. Journal of Clinical Oncology. 2018;**36**(5): 446-453

[56] Hölscher T, Baumann M, Kotzerke J, et al. Toxicity and efficacy of local ablative, image-guided radiotherapy in Gallium-68 prostate-specific membrane antigen targeted positron emission tomography-staged, castration-sensitive Oligometastatic prostate cancer: The OLI-P phase 2 clinical trial. European Urology Oncology. 2022;**5**(1):44-51

[57] Zilli T, Achard V, Dal Pra A, et al. Recommendations for radiation therapy in Oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus. Radiotherapy and Oncology. 2022;**176**: 199-207

[58] National Institutes of Health. Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases. Available from: https://clinicaltrials.gov/ct2/show /NCT02759783 [Accessed: October 14, 2022]

[59] National Institutes of Health. Management of Castration-Resistant Prostate Cancer with Oligometastases (PCS IX). Available from: https://clinica ltrials.gov/ct2/show/NCT02685397 [Accessed: October 14, 2022]

[60] National Institutes of Health. Salvage Radiotherapy Combined with Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS). Available from: https://clinicaltrials.gov/ct2/show/ NCT02274779 [Accessed: October 14, 2022]

[61] National Institutes of Health. Standard Treatment +/ SBRT in Solid Tumors Patients with Between 1 and 3 Bone-Only Metastases (STEREO-OS). Available from: https://clinicaltrials.gov/ ct2/show /NCT03143322 [Accessed: October 14, 2022]

[62] National Institutes of Health. PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases (STORM). Available from: https://clinica ltrials.gov/ct2/show/NCT03569241 [Accessed: October 14, 2022]

[63] Spratt DE, Zhang J, Santiago-Jiménez M, et al. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. Journal of Clinical Oncology. 2018;**36**(6):581-590

[64] Spratt DE, Huang HC, Michalski JM, et al. Validation of the performance of the decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG oncology/RTOG 0126. Journal of Clinical Oncology. 2022;**40**(6):269

[65] Jairath NK, Dal Pra A, Vince R Jr. A systematic review of the evidence for the decipher genomic classifier in prostate cancer. European Urology. 2021;**79**(3): 374-383

[66] Lonergan PE, Washington SL, Cowan JE. Risk factors for biopsy reclassification over time in men on active surveillance for early stage prostate cancer. Journal of Urology. 2020;**204**(6):1216-1221

[67] Vince RA, Jiang R, Qi J, et al. Impact of decipher biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. Prostate Cancer and Prostatic Diseases. 2022;**25**(4):677-683

[68] NRG Oncology. NRG-GU009. Available from: https://www.nrgoncolog y.org/Clinical-Trials/Protocol/nrg-g u009-1?filter=nrg-gu009-1 [Accessed: September 30, 2022]

[69] NRG Oncology. NRG-GU010. Available from: https://www.nrgoncolog y.org/Clinical-Trials/Protocol/nrg-g u010-1?filter=nrg-gu010-1 [Accessed: September 30, 2022]

[70] National Institutes of Health. Genomics in Michigan to AdJust Outcomes in Prostate cancer (G-MAJOR) for Men with Newly Diagnosed Favorable Risk Prostate Cancer. Available from: https://clinicaltrials.gov/ ct2/show/results/NCT04396808?view= results [Accessed: September 30, 2022]

[71] Esteva A, Feng J, van der Wal D, et al. Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digital Medicine. 2022;**5**(1):71
